Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
150estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-31 | actual | When the study began enrolling |
| Primary completion | 2026-07-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Papillary Renal Cell Carcinoma
Intervention
- Other: Observational, None intervention
Primary outcome
what the primary-completion date above is the date OFThe primary objective is to characterize the real-world PFS (rwPFS) with either sunitinib or sorafenib.
measured at least 6 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed